The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2012-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/jth.12036PMID 23083123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.

  2012cited by this paper
• Use of mouse models to study plasminogen activator inhibitor-1.

  2011cited by this paper
• Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.

  2011cited by this paper
• Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1

  2011cited by this paper
• Platelet Protease Nexin-1, a Serpin That Strongly Influences Fibrinolysis and Thrombolysis

  2010cited by this paper
• What has been learnt from the thrombin‐activatable fibrinolysis inhibitor‐deficient mouse?

  2010cited by this paper
• Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences.

  2010cited by this paper
• Towards a standardization of the murine tail bleeding model

  2010cited by this paper
• New insights into the molecular mechanisms of the fibrinolytic system

  2009cited by this paper
• Restoration of Plasma von Willebrand Factor Deficiency Is Sufficient to Correct Thrombus Formation After Gene Therapy for Severe von Willebrand Disease

  2008cited by this paper
• Development of sandwich‐type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma

  2007cited by this paper
• Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis

  2007cited by this paper
• Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice

  2005cited by this paper
• Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets.

  2003cited by this paper
• Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin‐activatable fibrinolysis inhibitor

  2003cited by this paper
• Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.

  2002cited by this paper
• Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.

  2002cited by this paper
• In vivo regulation of plasminogen function by plasma carboxypeptidase B.

  2002cited by this paper
• Enhanced Fibrinolytic Potential in Mice with Combined Homozygous Deficiency of α2-antiplasmin and PAI-1

  2001cited by this paper
• Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice

  2001cited by this paper
• A Tail Vein Bleeding Time Model and Delayed Bleeding in Hemophiliac Mice

  2001cited by this paper
• Four Cases of Bleeding Diathesis in Children due to Congenital Plasminogen Activator Inhibitor-1 Deficiency

  2000cited by this paper
• Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice.

  2000cited by this paper
• Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.

  2000cited by this paper
• Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.

  1999cited by this paper
• Differential Role of Components of the Fibrinolytic System in the Formation and Removal of Thrombus Induced by Endothelial Injury

  1999cited by this paper
• Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding.

  1999cited by this paper
• Vitronectin inhibits the thrombotic response to arterial injury in mice.

  1999cited by this paper
• Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice.

  1998cited by this paper
• A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.

  1998cited by this paper
• Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.

  1997cited by this paper
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex*

  1996cited by this paper
• Immunoassay of Murine t-PA, u-PA and PAI-1 Using Monoclonal Antibodies Raised in Gene-inactivated Mice

  1995cited by this paper
• Characterization of the murine plasma fibrinolytic system.

  1994cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

  1993cited by this paper
• Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.

  1993cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.

  1993cited by this paper
• Simplified mammalian DNA isolation procedure.

  1991cited by this paper
• A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.

  1991cited by this paper
• Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

  1989cited by this paper
• Plasminogen activator inhibitor (PAI‐1) in plasma and platelets

  1988cited by this paper
• Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencing

  1986cited by this paper
• The primary inhibitor of plasmin in human plasma.

  1976cited by this paper

• Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.

  2024cites this paper
• Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model.

  2023cites this paper
• In vivo near-infrared fluorescent fibrin highlights growth of nerve during regeneration across a nerve gap

  2022cites this paper
• Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).

  2021cites this paper
• Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics

  2021cites this paper
• S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.

  2021cites this paper
• Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease

  2020cites this paper
• Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE−/−–LDLR−/− Double-Knockout Mice

  2020cites this paper
• Defective fibrin deposition and thrombus stability in Bambi −/− mice are mediated by elevated anticoagulant function

  2019cites this paper
• Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague

  2019influential citation
• Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.

  2018cites this paper
• Category : Thrombosis and Hemostasis Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding Running title : Defective TAFI activation in hemophilia A

  2018cites this paper
• Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity

  2018cites this paper
• The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer

  2017cites this paper
• Sulfamide as Zinc Binding Motif in Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).

  2016cites this paper
• Regulation of the Activation and Function of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI)

  2016cites this paper
• Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.

  2015cites this paper
• Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke.

  2015cites this paper
• Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity

  2015cites this paper
• Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFI.

  2014cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor: A Putative Target to Enhance Fibrinolysis

  2013cites this paper
• TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation

  2013cites this paper
• Insights into thrombin activatable fibrinolysis inhibitor function and regulation

  2013cites this paper
• Regulation of fibrinolysis by metallo-carboxypeptidase TAFI and its pathophysiology

  2013cites this paper
• Yersinia pestis Mediated Defense against - Fibrin Facilitates Both Innate and T Cell

  2013cites this paper
• Fibrin Facilitates Both Innate and T Cell–Mediated Defense against Yersinia pestis

  2013cites this paper
• Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a

  2013cites this paper
• Antithrombotic therapy: current status and future developments

  2012cites this paper